Provention Bio, Inc.
PRVBDelisted Apr 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001695357
Provention Bio, Inc. was delisted on Apr 27, 2023; its insiders filed their last Form 4 on Apr 28, 2023; 183 institutions reported holding it in 13F filings for Q1 2023, worth $1.47B in total; Fairfax Financial was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 183
- Q1 2023, +50 vs. previous quarter
- 13F value
- $1.47B
- Reported value at the end of Q1 2023
- Superinvestors holding
- 1
- At the end of Q1 2023
Superinvestors holding PRVB, Q1 2023
1 superinvestor reports holding Provention Bio, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Fairfax Financial
Prem Watsa
0.4%
Provention Bio, Inc.'s share of the portfolio
- Shares
- 277,000
- Value
- $6.67M
Latest insider trades
Open-market purchases and sales by Provention Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 18, 2023 (view filing)8:57 PM ET | Apr 14 | 4 days | Sessa Capital IM, L.P. and 4 others10% Owner | SSale | −2.19M | $24.32 | −$53.3M | −12.3%15.6M after | |
| Feb 14, 2023 (view filing) | Feb 10-13 | 4 days | Leon FranciscoChief Scientific Officer | SSale | −76.0K | $10.09 | −$766.4K | −4.6%1.57M after | 2 lots |
| Feb 14, 2023 (view filing) | Feb 10 | 4 days | Hoitt JasonChief Commercial Officer | SSale | −4.50K | $10.00 | −$45.0K | −100.0%0 after | |
| Feb 14, 2023 (view filing) | Feb 10-13 | 4 days | Palmer AshleighDirector and CEO | SSale | −75.8K | $10.09 | −$764.9K | −2.9%2.57M after | 2 lots |
| Jan 20, 2023 (view filing)4:10 PM ET | Jan 18 | 2 days | Sessa Capital IM, L.P. and 4 others10% Owner | SSale | −3.00M | $9.40 | −$28.2M | −20.2%11.9M after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Palmer AshleighDirector and CEO | SSale | −24.2K | $10.27 | −$248.2K | −0.9%2.57M after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Leon FranciscoChief Scientific Officer | SSale | −24.0K | $10.27 | −$246.6K | −1.5%1.57M after | |
| Dec 30, 2022 (view filing) | Dec 29 | 1 day | Leon FranciscoChief Scientific Officer | SSale | −187.0K | $10.26 | −$1.92M | −10.6%1.57M after | |
| Dec 29, 2022 (view filing) | Dec 27 | 2 days | Leon FranciscoChief Scientific Officer | SSale | −10.7K | $10.00 | −$106.7K | −0.7%1.57M after | |
| Dec 27, 2022 (view filing) | Dec 22-23 | 5 days | Leon FranciscoChief Scientific Officer | SSale | −1.94K | $10.00 | −$19.4K | −0.1%1.57M after | 2 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in Provention Bio, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 8,879,023 | $214.0M | 8.81% | −6,000,000−40.3% | Reduced |
| BlackRock Inc. | 5,666,347 | $136.6M | 0.00% | +86,743+1.6% | Added |
| Vanguard Group Inc | 4,178,440 | $100.7M | 0.00% | +35,696+0.9% | Added |
| Adage Capital Partners GP, L.L.C. | 3,641,012 | $87.7M | 0.20% | +1,121,755+44.5% | Added |
| Pentwater Capital Management LP | 3,135,000 | $75.6M | 1.25% | +3,135,000 | New |
| UBS Oconnor LLC | 2,925,000 | $70.5M | 1.68% | +2,925,000 | New |
| State Street Corp | 1,732,506 | $41.8M | 0.00% | +174,268+11.2% | Added |
| Magnetar Financial LLC | 1,484,708 | $35.8M | 0.70% | +1,484,708 | New |
| Geode Capital Management, LLC | 1,436,689 | $34.6M | 0.00% | +114,500+8.7% | Added |
| Alpine Associates Management Inc. | 1,364,900 | $32.9M | 1.76% | +1,364,900 | New |